News

Mr Gleeson joined The Quigley Corporation in 1998 and has served in management positions including corporate controller of the company since 2004. Mr Gleeson’s career includes his tenure

Merck has informed the company that, in light of results reported in a recently published study comparing laser treatment and intravitreal injections of triamcinolone acetonide in patients with

The recalled patches are from lot number 92461850, have expiration dates of August 31, 2009 and were manufactured by Watson Laboratories. The affected lot of fentanyl transdermal system

Leti Laboratories will provide product support and product packaging control, coordinate sales to other European distributors, distribute the company’s products in Spain and Portugal, act as the registered

The application, filed by Centocor late in 2007, seeks approval to market ustekinumab for the treatment of adult patients with chronic moderate to severe plaque psoriasis. The FDA

John Kovach, president and CEO of Lixte, said: “Lixte previously reported that lead compounds from each of two different classes of pharmacologic agents have significant inhibitory activity against

Ron Creeley, vice president of marketing and sales for Simulations Plus, said: “We’re very pleased that the FDA’s cardiovascular and renal products division has licensed our ADMET Predictor

The priority review is granted to applications in which a new indication or new drug product, if approved, has the potential to present a safe and effective therapy

Under the terms of the agreement, Archemix will receive an upfront payment of $6 million. Ribomic has the option, upon payment of a further fee, to convert the